News for Adverum Biotechnologies, Inc. (ADVM)

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (”œAdverum” or

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

**media[595473]**

Adverum Biotechnologies (ADVM) reports Q4 GAAP EPS of -$1.96, missing estimates by $0.60. Explore the financial performance and implications.

PR NewswireNEW YORK, April 14, 2025 NEW YORK, April 14, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotec

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adverum Bi

NEW YORK, April 12, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (”œAdverum” or t

REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. ( ADVM) today announced that the Compensation Committee of Adverum's Bo

**media[586383]**

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision ou

**media[556087]**

**media[553871]**

REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. ( ADVM) today announced that the Compensation Committee of Adverum's Boa

REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting

REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. ( ADVM), a clinical-stage company pioneering the use of gene therapy as

**media[533427]**

**media[485661]**

ADVM stock touches 52-week low at $5.64 amid market challenges

REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. ( ADVM) today announced that on November 17, 2024, the Compensation Comm